# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Daiichi Sankyo and AstraZeneca's ENHERTU has now been granted eight Breakthrough Therapy Designations with latest based o...
FDA approves AstraZeneca's Imfinzi with chemotherapy for early-stage lung cancer, based on pivotal AEGEAN trial. Imfinzi sh...
AstraZeneca is raising concerns that a manufacturing site could be relocated to France, putting an investment in jeopardy.
Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch r...
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The ...
Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare d...